Year Approved** | ||||
Drug (INN)* | Trade Name | Developer | FDA | |
Gemtuzumab Ozogamicin | Maylotarg® | Wyeth/Pfizer | 2000 (Witdrawn) | |
Gemtuzumab Ozogamicin | Maylotarg® | Wyeth/Pfizer | 2017 (Reintroduced) | |
Brentuximab Vedodin | Adcetris® | Seattle Genetics /Takeda | 2011 | |
Ado-trastuzumab emtansine | Kadcyla® | Genentech /Roche | 2013 | |
Inotuzumab Ozogamicin | Besponsa® | Wyeth /Pfizer | 2017 | |
Polatuzumab vedotin-piiq | Polivy™ | Genentech /Roche | 2019 | |
Enfortumab Vedotin-ejfv | Padcev™ | Astellas /Seattle Genetics | 2019 | |
Fam-trastuzumab deruxtecan-nxki | Enhertu® | Daiichi Sankyo /AstraZeneca | 2019 | |
Belantamab mafodotin-blmf | Blenrep™ | GSK /GlaxoSmithKline | 2020 | |
Sacituzumab govitecan-hziy | Trodelvy™ | Gilead /Immunomedics | 2020 | |
* Link to drug description ** Link to package insert